U.S. Markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.09 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.88 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    +0.25 (+0.31%)
     
  • Gold

    1,668.30
    -3.70 (-0.22%)
     
  • Silver

    19.01
    -0.02 (-0.13%)
     
  • EUR/USD

    0.9802
    -0.0017 (-0.1764%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1148
    +0.0025 (+0.2230%)
     
  • USD/JPY

    144.6700
    +0.2270 (+0.1572%)
     
  • BTC-USD

    19,251.45
    -15.14 (-0.08%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.89 (-1.84%)
     

Smith & Nephew Shares Fall On Lower Margins As Cost Headwinds Hit Q2 Profit

·1 min read
  • Smith & Nephew Plc (NYSE: SNN) reported Q2 revenue of $1.29 billion, up 1.2% on an underlying basis but down 3.1% on a reported basis, including a 430 basis point foreign exchange headwind.

  • Orthopedics revenue declined 1.1%, or by 4.9% on a reported basis, reflecting execution and supply chain challenges.

  • Sports Medicine and ENT were up 1.9%, but down 2.4% on a reported basis, with growth “significantly impacted” by the Covid-related lockdown in China.

  • Advanced wound management grew 3.8% but fell 1.3% on a reported basis, with all regions and segments contributing.

  • Its operating profit margin was 9.3%, compared to 9.2% a year ago, while EPS slipped to 20.2 cents from 23.4 cents.

  • The company’s 1H trading profit totaled $440 million, down from $459 million, as the margin declined from 17.6% to 16.9%, reflecting higher input inflation.

  • Guidance: Smith & Nephew unchanged full-year underlying revenue growth guidance of 4.0% - 5.0%.

  • Meanwhile, its trading profit margin was expected to be around 17.5%, reflecting a prolonged inflationary impact and continued external supply challenges.

  • “After only a few months at Smith & Nephew it is clear to me that we have many more opportunities than challenges,” said CEO Deepak Nath.

  • Nath said orthopedics continued to be held back by execution and supply chain challenges.

  • Price Action: SNN shares are down 10.30% at $26.32 during the market session on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.